This study investigates the impact of KRAS mutations and their co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). Researchers analyzed data from 803 patients with PDAC at MD Anderson Cancer Center, finding that KRAS mutation status and specific subtypes were prognostic for overall survival (OS). Patients with KRAS wildtype tumors had a median OS of 38 months, while those with KRAS G12D mutations had a shorter median OS of 22 months. KRAS G12R mutations showed a similar OS to wildtype tumors. KRAS G12D mutations were more common in metastatic tumors, while KRAS G12R mutations were more common in well-differentiated tumors. These findings were validated in an external cohort from the PanCAN KYT dataset. The study also examined co-mutations with KRAS, finding that TP53 was the most frequently co-mutated gene with KRAS. ARID1A mutations were associated with worse OS, while SMAD4 mutations were associated with better OS. KRAS G12D mutations were associated with worse outcomes compared to KRAS G12R mutations. The study highlights the importance of considering KRAS mutation subtypes and co-mutations in the treatment of PDAC, suggesting that allele-specific approaches may be beneficial. The findings suggest that KRAS G12R mutations may have a less aggressive biological profile compared to KRAS G12D mutations. The study also notes that co-mutations can influence clinical outcomes, and that further research is needed to understand the full impact of these mutations on PDAC. The study concludes that targeting KRAS in PDAC requires consideration of the specific mutation subtypes and co-mutations present.This study investigates the impact of KRAS mutations and their co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). Researchers analyzed data from 803 patients with PDAC at MD Anderson Cancer Center, finding that KRAS mutation status and specific subtypes were prognostic for overall survival (OS). Patients with KRAS wildtype tumors had a median OS of 38 months, while those with KRAS G12D mutations had a shorter median OS of 22 months. KRAS G12R mutations showed a similar OS to wildtype tumors. KRAS G12D mutations were more common in metastatic tumors, while KRAS G12R mutations were more common in well-differentiated tumors. These findings were validated in an external cohort from the PanCAN KYT dataset. The study also examined co-mutations with KRAS, finding that TP53 was the most frequently co-mutated gene with KRAS. ARID1A mutations were associated with worse OS, while SMAD4 mutations were associated with better OS. KRAS G12D mutations were associated with worse outcomes compared to KRAS G12R mutations. The study highlights the importance of considering KRAS mutation subtypes and co-mutations in the treatment of PDAC, suggesting that allele-specific approaches may be beneficial. The findings suggest that KRAS G12R mutations may have a less aggressive biological profile compared to KRAS G12D mutations. The study also notes that co-mutations can influence clinical outcomes, and that further research is needed to understand the full impact of these mutations on PDAC. The study concludes that targeting KRAS in PDAC requires consideration of the specific mutation subtypes and co-mutations present.